



Drug-drug interactions (DDIs) repre-
sent a common cause of adverse drug reac-
tions (ADRs), particularly in patients using 
multiple drugs [1] inducing an impairment 
of quality of life and an increase in health-
care costs [2]. Therapeutic drug monitoring 
(TDM) is useful to improve drug safety re-
ducing the development of ADRs, particu-
Why we describe this case
Drug-drug interactions are common in 
patients using multiple drugs. This case 
report suggests that, when a drug switch 
is not possible, the therapeutic drug moni-
toring may help physicians in the mana-
gement of treatments that usually could 
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We describe a 67-year-old man with medical history of focal post-stroke seizure and type 2 
diabetes mellitus treated with carbamazepine, clobazam, gliclazide, insulin glargine, and 
omeprazole we visited for the onset in the last 7 days of asthenia, cough with mucus, breathing 
difficulty, chest pain, and weight loss. After clinical and laboratory tests, pulmonary tuberculosis 
was diagnosed, and a treatment with isoniazid, ethambutol, pyrazinamide rifampicin, and 
pyridoxine was started. Therapeutic drug monitoring of tuberculosis treatment documented that 
all drugs were in normal therapeutic range. Four days after the beginning of the treatment, we 
documented the improvement of fever, and three days later the patient showed sleepiness, visual 
disorder and asthenia. Clinical and pharmacological evaluation suggested a carbamazepine 
toxicity probably related to a drug interaction (Drug Interaction Probability Scale score = 6). The 
impossibility to switch carbamazepine for another antiepileptic drug, due to a resistant form of 
seizure, induced the discontinuation of tuberculosis treatment, resulting in the normalization 
of serum carbamazepine levels in one day (10 µg/ml) and in the worsening of fever, requiring 
a new clinical and pharmacological evaluation. The titration dosage of carbamazepine and its 
therapeutic drug monitoring allowed to continue the treatment with both antitubercular drugs 
and carbamazepine, without the development of adverse drug reactions. To date, tuberculosis 
treatment was stopped and clinical evaluation, radiology and microbiology assays documented 
the absence of tubercular infection and no seizures appeared (carbamazepine dosage 800 mg/
bid; serum levels 9.5 µg/ml). 
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larly during the treatment with drugs that 
have a narrow therapeutic index.
CAse report
A 67-year-old man (weight  =  65 kg, 
height = 1.68 m) was referred for evalua-
tion on January the 20th, 2014 owing to the 
onset in the last 7 days of asthenia, cough 
with mucus, breathing difficulty, chest pain, 
and weight loss (1.8 kg). His medical his-
tory reported focal post-stroke seizure un-
responsive to several antiepileptic drugs (i.e., 
oxcarbazepine, topiramate, levetiracetam, la-
motrigine, valproic acid) and well-controlled 
type 2 diabetes mellitus (HbA1c < 7%).
Medications included carbamazepine 
(800 mg/bid), clobazam (100 mg/daily), 
gliclazide (30 mg/tid), insulin glargine (100 
IU), and omeprazole (20 mg/daily). On 
physical examination, blood pressure was 
108/70 mmHg, heart rate = 83 beats/min, 
respiratory rate = 20 breaths/min, tempera-
ture = 38.1°C, SpO2 = 98% on room air; tu-
berculin skin test was performed.
Laboratory test revealed high levels of C-
reactive protein (CRP = 18 mg/l), erythro-
cyte sedimentation rate (ESR = 62 mm/h) 
and white blood cells (WBC = 17,910 cells/
µl). Other biochemical tests were in normal 
range (Table I).
Chest X-ray showed multifocal opacities 
in the right upper lobe with thickening and 
upward shift of the minor fissure, pleural ef-





Glucose (mg/dl) 89 70-100
Creatinine clearance (ml/min) 87 85-130
Serum creatinine (mg/dl) 0.75 0.7-1.2
Potassium (mEq/l) 3.9 3.6-5
Total cholesterol (mg/dl) 165 < 220
LDL-cholesterol (mg/dl) 95 < 130
HDL-cholesterol (mg/dl) 40 35-39
Triglycerides (mg/dl) 72 50-150
Aspartate aminotransferase (IU/l) 26 8-48
Alanine aminotransferase (IU/l) 22 7-55
C-reactive protein (mg/l) 18 0.5-10
Erythrocyte sedimentation rate (mm/h) 62 0-22
White blood cells (cells/µl) 17,910 4,500-11,000
table I. Laboratory 
findings at admission
days later, tuberculin skin test proved positive, 
as confirmed by interferon-gamma release 
blood test, while microbiology of sputum 
documented the presence of Mycobacterium 
tuberculosis. Pulmonary tuberculosis was di-
agnosed and a treatment with a fixed-dose 
combination of isoniazid 75 mg/day, etham-
butol 275 mg/day, pyrazinamide 400 mg/day 
and rifampicin 150 mg/day (Rimstar®) + 
pyridoxine (50 mg/day) was started. Two days 
later, the TDM of tuberculosis treatment, 
performed 2 hours after drug administration, 
documented that all drugs were in normal 
therapeutic range: isoniazid = 4.6 µg/ml (nor-
mal range = 3-6 µg/ml); ethambutol = 4 µg/
ml (normal range  =  2-6 µg/ml); pyrazin-
amide = 32.8 µg/ml (normal range = 20-50 
µg/ml); rifampicin  =  8.5 µg/ml (normal 
range = 8-24 µg/ml). Four days after the be-
ginning of drug treatment, we documented 
the improvement of fever (36.8°C) but, three 
days later, the patient showed sleepiness, vi-
sual disorders, and asthenia. On physical ex-
amination, he was conscious and oriented in 
both time and space and presented somno-
lence, ataxia, and nystagmus; blood pressure 
was 97/68 mmHg with a pulse heart rate = 96 
beats/min; electrocardiography revealed a 
cardiac block. Other causes of conscious dis-
orders e.g. trauma, substance abuse, and in-
fections were ruled out. Laboratory analysis 
and abdominal ultrasound examinations were 
negative; renal, liver, and heart failures were 
ruled out. Carbamazepine intoxication was 
postulated, and TDM confirmed it (serum 
carbamazepine levels = 16.60 µg/ml; normal 
range = 6-12 µg/ml). Pharmacological evalu-
ation suggested a possible DDI between tu-
berculosis treatment and carbamazepine 
(Drug Interaction Probability Scale score = 6).
The impossibility to switch from carbam-
azepine to another antiepileptic drug, due to 
a resistant form of seizure, induced the dis-
continuation of tuberculosis treatment, re-
sulting in the normalization of serum carba-
mazepine levels in one day (10 µg/ml). Two 
days later, we recorded a worsening of fever 
(37.9°C) that required a new clinical and 
pharmacological evaluation. Considering 
history, co-morbidity and drug treatment, 
tuberculosis treatment was re-administered 
and carbamazepine was titrated in 3 admin-
istrations/day (total = 400 mg/day), result-
ing in a good control of clinical symptoms. 
TDM of carbamazepine performed one 
day later was in normal range (10.1 µg/ml).
One- and two-month follow-up revealed 
a good control of tubercular disease, while 
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TDM showed normal levels of both car-
bamazepine (10.0 µg/ml) and tuberculosis 
drugs (isoniazid  =  4.7 µg/ml; ethambu-
tol =  l4.2 µg/ml; pyrazinamide = 34.5 µg/
ml; rifampicin = 9.1 µg/ml), without the de-
velopment of seizure or ADRs. Tuberculosis 
treatment was discontinued and switched to 
a fixed-dose combinations of isoniazide + ri-
fampicin. In October, tuberculosis treatment 
was stopped and clinical evaluation, as well 
as radiology and microbiology assays, docu-
mented the absence of tubercular infection. 
No seizure or ADRs appeared (carbamaze-
pine dosage = 800 mg/bid; serum levels = 9.5 
µg/ml). Time course of drug treatment dur-
ing the study is reported in Table II.
dIsCussIon
Here we report the case of a 67-year-old 
man with type 2 diabetes mellitus and re-
sistant epilepsy responsive to carbamazepine 
and clobazam. Due to the development of 
tuberculosis, the patient was hospitalized 
and treated with isoniazid, ethambutol, 
pyrazinamide, and rifampicin, with a good 
control of tuberculosis.
It has been reported that in patients with 
tuberculosis, diabetes contributes to increase 
severity [3], reducing the response to tuber-
culosis treatment [4]. In our patient, clinical 
time symptoms/laboratory tests treatment
Admission
January 20th, 2014
Asthenia, cough with mucus, breathing difficulty, chest pain and 
weight loss
Carbamazepine (1,600 mg/day)
January 23rd, 2014 diagnosis of tuberculosis start Rimstar® + pyridoxine
January 25th, 2014 TDM of tuberculosis treatment: normal range
January 29th, 2014 Improvement of fever
February 1st, 2014 Sleepiness, visual disorder, and asthenia; blood pressure = 97/68 
mmHg, pulse heart rate = 96 beats/min; cardiac block
Increase in plasma carbamazepine levels
stop Rimstar® and pyridoxine
February 2nd, 2014 Normal plasma carbamazepine levels
February 4th, 2014 Worsening of fever start Rimstar® + pyridoxine
reduce carbamazepine (total 400 mg/day)
February 5th, 2014 Normal plasma carbamazepine levels
March, 2014 Normal plasma carbamazepine levels
No seizures
No adverse drug reactions
April, 2014 Normal plasma carbamazepine levels
No seizures
No adverse drug reactions
Rimstar® switched to isoniazide + rifampicin
October, 2014 No tuberculosis Stop isoniazide + rifampicin
Increase carbamazepine to 1,600 mg/day
table II. Time course of 
drug treatment during 
the study
Main questions a doctor should ask him/herself in this situation
 y Have I excluded other causes able to induce symptoms?
 y Can I change the treatment?
 y Can I evaluate the plasma levels of each drug?
evaluation documented an improvement of 
tuberculosis symptoms, while TDM revealed 
that tuberculosis drugs were in normal range. 
However, 7 days after the beginning of tu-
berculosis treatment, the patient lamented 
sleepiness, visual disorder, and asthenia. Sev-
eral papers showed that the administration 
of isoniazid in a patient treated with carba-
mazepine may induce the development of 
liver failure [5,6] able to induce conscious 
disorders.
Laboratory and clinical evaluation exclud-
ed secondary causes of conscious disorders 
(i.e. alcohol and substance abuse, encepha-
litis, hepatitis, neuroleptic malignant syn-
drome, drug toxicity).
Pharmacological evaluation hypothesized 
a carbamazepine intoxication related to a 
drug-drug interaction. In fact, carbamaze-
pine is highly bound to plasma proteins (75-
80%), with an half-life of 12-20 hours, and 
is metabolized in the liver by cytochrome 
P450 (CYP3A4) [7]; isoniazid and eth-
ambutol are strong and weak CYP3A4 in-
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and tuberculosis and without the develop-
ment of ADRs.
The Summary of Product Characteristics 
(SPCs) represents the primary source of in-
formation about DDIs for health care profes-
sionals. Unfortunately, DDIs cannot be listed 
exhaustively, consequently the information 
on potential DDIs may be insufficiently de-
scribed, due to the limited space in the SPC.
In fact, in the present case, SPC suggests 
to evaluate carefully the co-administration 
of carbamazepine during the treatment 
with isoniazid, but when it is not possible 
to change the drugs, TDM is needed to op-
timize the therapeutic efficacy and safety of 
carbamazepine.
Key points
 y Drug-drug interactions (DDIs) may be common during a multiple therapy
 y DDIs must be considered during a differential diagnosis
 y Clinical conditions as well as therapeutic drug monitoring may be important during the 
clinical management
hibitors, respectively [8,9]. Therefore, these 
drugs probably slowed the elimination of 
carbamazepine in our patient.
In fact, TDM documented high serum 
carbamazepine levels, and the discontinu-
ation of tuberculosis treatment induced a 
decrease in serum carbamazepine levels, with 
a worsening of tuberculosis.
In agreement with our previous papers 
[10,11], using the Drug Interaction Prob-
ability Scale (DIPS), we hypothesized an 
interaction between tuberculosis treat-
ment and carbamazepine. The titration 
of carbamazepine dosage and its TDM 
allowed continuation of combined treat-
ment with a good control both of seizure 
